Solid Biosciences Inc. (SLDB)

Solid Biosciences Inc. is trading at $8.99, down 1.21% on the session. The 50 day average sits at $8.60 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 57.3, which reads as strong, and MACD is bullish crossover. Volume is below average.

The nearest support is around $8.29 with resistance near $11.45, so that band frames the current range. Average daily movement is roughly $0.51, or about 5.7% of the share price, which is what any stop placement has to allow for. The overall health score of 55 out of 100 combines a trend score of 56, momentum of 72 and a risk score of 28.

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in preclinical phase; SGT-601 the treatment of TNNT2-mediated dilated cardiomyopathy, which is in preclinical phase; SGT-401 for the treatment of BAG3-mediated dilated cardiomyopathy that is in preclinical phase; SGT-701 for treatment of rare inherited disease characterized by mutations in the RBM20 gene, which is in discovery phase; and other drugs for the treatment of cardiac and other diseases. In addition, the company is involved in developing platform technologies, including capsid libraries; genetic regulators, such as promoters, UTRs, and introns; immunomodulation technologies; manufacturing purity; and dual gene expression, a technology for packaging multiple transgenes into one capsid. The company has collaboration and license agreement with Ultragenyx Pharmaceutical Inc.; and a license agreement with the University of Washington, University of Missouri, University of Florida, and ICS Maugeri S.p.A. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Charlestown, Massachusetts.